Cancer therapies

 

Current statistics published by the World Health Organisation (WHO) indicate that there are about 24.6 million people around the world who are suffering from cancer. The WHO forecasts that this figure will be increasing to about 30 million by the year 2020, which underlines the tremendous medical need for effective forms of treatment. Alongside cardiovascular diseases, cancer is now one of the most frequent causes of death from illness in the Western industrialized nations. An increasing amount of progress has been made in the cancer treatment field in recent years. However, many currently as standard established therapies are a great strain on the patients' immune system, which leads to additional weakening of their overall condition. In order to be able to prevent this in future, cancer research is concentrating on the development of treatment and drugs that are not just effective but also highly tolerable.

Immune treatment which acts specifically at the cellular level is considered to be a particularly promising option. The toll-like receptor 9 (TLR9) is considered to play a central role in this context. Consequently, there are high hopes in the immune treatment field for substances which bond to TLR9 and lead to greater activation of the immune system. These substances are known as TLR9 agonists and have been major research subjects at international pharmaceutical and biotechnology companies for a number of years now.

With its  cancer therapy with dSLIM and  cell-based gene therapy , MOLOGEN AG is working on two promising approaches that aim to increase activation of the immune system and are currently being investigated in clinical studies.

 

For further information please contact:  Arlett Killat

 

MOLOGEN®, MIDGE® and dSLIM® are registered trademarks of MOLOGEN AG